ArtivionAORT
Recorded

Artivion Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Review the key takeaways and the transcript of this earnings call.

Period 0Duration28 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Bill PlovanicSenior Analyst

All right. Good morning. Welcome to the Canaccord MedTech, Diagnostics and Digital Health & Services Forum. My name is Bill Plovanic. I am Senior Analyst here with Canaccord. With us up first, we have a fireside chat with Artivion, and we have the Chairman, President and Chief Executive Officer, Pat Mackin, and the Chief Financial Officer, Chief Operating Officer, Lance Berry. With that, I am going to just sit down and get going here. All right, we are going to dig right in. You guys just had earnings. I think all of us are just getting to the end of earnings. So, Q3 was a solid quarter on the headline numbers. Revenue, EBITDA, and EPS were all ahead of expectations, but the loss of PerClot and a slower-than-hoped AMDS starter set ramp kind of reset our expectations. The stock pulled back, and at the same time, you now have the AMDS under PMA and NEXUS launching on January 1st.

Bill PlovanicSenior Analyst

Before I get into all this, it seems like the setup for 2027 is really good here, but the stock is obviously off the quarter, didn't trade so well. As you talk to investors, what is the biggest thing you hear, the one thing you think they are missing as they are looking at the company today?

Lance BerryCFO and COO

Yeah, so I think, one, I think there is just a lot of focus on the very near term. I think people that if they are looking at 2027 and they are really thinking through the things that we have set up for 2027, I don't think the stock would be doing what it is doing right now. I think there are a lot of questions around, what does the guide mean for Q4? So very near-term things. But if you step back, everything that we have been setting up for 2027 is really still intact. AMDS is still a huge opportunity for us. We are going to be launching NEXUS on January 1. Yes, we have this PerClot that is going away, but that is really an inorganic thing.

Lance BerryCFO and COO

It is something we sold a long time ago, and if you look at it more on an organic basis, I think the street is at close to 10% top-line growth and high teens EBITDA growth, which is kind of where we are telling people every year at the beginning of the year that we are going to try and accomplish. Really, I think if you look on into 2027, as you pointed out, there are a lot of good things that we have going on, and there is really no change in what we are typically talking about for the next year.

Bill PlovanicSenior Analyst

Okay. Then in terms of the 2027 framework and the guidance, you already talked about the tightening and the taking PerClot out. Is there anything in the core portfolio tracking differently than you expected six months ago?

Lance BerryCFO and COO

Well, honestly, versus six months ago, that's a good question. Really, if you look at what we did on guidance for 2026, we basically just maintained the midpoint of our guidance for the second half of the year, and we have a little bit of timing difference in our preservation services business between Q3 and Q4. Even if you look at that for the full year, it's going to come in right in line or probably a little better than what we expected at the beginning of the year. So, we would say things are overall very much the same, which I would say would be reflected in what we did with our guidance.

Bill PlovanicSenior Analyst

All right. Last on guidance, I promise, and then we'll get into the products. NEXUS is expected to be EBITDA neutral in 2027. You got the R&D clinical spending moving towards 7%-8% of sales. What's the right framework for EBITDA margin expansion beyond 2027?

Lance BerryCFO and COO

Yeah, I think we've talked a lot about how we think our company has very durable top-line growth and a really good opportunity for EBITDA leverage. We have the normal G&A leverage that any kind of a sub-$1 billion company would typically have. Our sales force is probably a little more leverageable than most Medtronic companies because our reps don't have to stand in every single case. Then the last thing is these new products that we're bringing to the market in the U.S. are all pretty meaningfully higher gross margin than our corporate average, so we have an opportunity for gross margin expansion over time.

Lance BerryCFO and COO

With all three of those things in place, we talk about trying to be a double-digit growth business with EBITDA leverage that gets us to EBITDA growth twice top-line growth, and to be able to do that for years and years and years.

Bill PlovanicSenior Analyst

That's an unchanged. 2027 is just, it would be, but you got to strip out the PerClot.

Lance BerryCFO and COO

I think the PerClot thing is, and maybe just for a little bit of background for people, it's a product that we off-strategy product that we sold in 2021, but it's a PMA product, and the buyer had to scale up their own manufacturing, which for a PMA product just takes years, literally. It's been harder for them than they anticipated. It's drug out longer than we expected, and we finally got notice just recently that they have all their approvals, they're ready to go, they're going to take it over, which we are ecstatic about. We have no desire to be an OEM manufacturer for this product that we sold five years ago. That's coming to an end. So there is a little bit of revenue that's in the model, a little bit of earnings that'll go away, but it's really not indicative of the long-term business.

Lance BerryCFO and COO

You can almost think about a discontinued operation that just wasn't put in discontinued operations.

Bill PlovanicSenior Analyst

Okay. AMDS, I think, has been the challenge this year, definitely from a starter kit standpoint. How do you feel just on AMDS? Has the sell-through, the utilization for the accounts you brought on board, how is that tracking to your original expectations? Are there use cases that you expected, didn't expect, kind of getting in the weeds on AMDS?

Pat MackinPresident and CEO

Yeah. Just general thoughts. Just to remind people, there are two sources of revenue for AMDS.

Pat MackinPresident and CEO

There is the starter set. There are four different part numbers. You have to buy all four. It is $100,000 up front. Then there is the actual implant. You have a case, you use a device, and then you replenish and reorder. If you go back to 2025, we actually did better than we thought on the starter sets. We actually had a great year, and we actually beat our expectations on starter sets. We got into Q1, and that is when we kind of ran up against the wall on the starter sets, which is when we kind of changed our guidance. The starter sets have been harder because it is really an administrative task.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day